Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 2
2004 7
2005 19
2006 7
2007 15
2008 14
2009 26
2010 32
2011 23
2012 38
2013 51
2014 73
2015 64
2016 64
2017 49
2018 68
2019 64
2020 67
2021 55
2022 47
2023 36
2024 20

Text availability

Article attribute

Article type

Publication date

Search Results

735 results

Results by year

Filters applied: . Clear all
Page 1
Successful medical management of a pituitary macroadenoma with features of resistant acromegaly and hyperprolactinemia using pasireotide.
Baagar KA, Sadiq A, Khan AA, Dabbous Z, Rohani Z. Baagar KA, et al. Qatar Med J. 2024 Mar 14;2024(1):17. doi: 10.5339/qmj.2024.17. eCollection 2024. Qatar Med J. 2024. PMID: 38654814 Free PMC article.
BACKGROUND: The somatostatin analog, pasireotide, is used for the treatment of acromegaly after the failure of surgery and/or first-line medical treatment. ...The patient developed type 2 diabetes as a side effect of pasireotide; however, this was well-controlled wi …
BACKGROUND: The somatostatin analog, pasireotide, is used for the treatment of acromegaly after the failure of surgery and/or first-l …
The Novel SSTR3 Agonist ITF2984 Exerts Antimitotic and Proapoptotic Effects in Human Non-Functioning Pituitary Neuroendocrine Tumor (NF-PitNET) Cells.
Di Muro G, Catalano R, Treppiedi D, Barbieri AM, Mangili F, Marra G, Di Bari S, Esposito E, Nozza E, Lania AG, Ferrante E, Locatelli M, Modena D, Steinkuhler C, Peverelli E, Mantovani G. Di Muro G, et al. Int J Mol Sci. 2024 Mar 23;25(7):3606. doi: 10.3390/ijms25073606. Int J Mol Sci. 2024. PMID: 38612419 Free PMC article.
We treated cells derived from 23 NF-PitNETs with ITF2984, and a subset of them with octreotide, pasireotide (SRLs with high affinity for SSTR2 or 5, respectively), or cabergoline (DRD2 agonist) and we measured cell proliferation and apoptosis. ...
We treated cells derived from 23 NF-PitNETs with ITF2984, and a subset of them with octreotide, pasireotide (SRLs with high affinity …
Predictive factors and the management of hyperglycemia in patients with acromegaly and Cushing's disease receiving pasireotide treatment: post hoc analyses from the SOM230B2219 study.
Feldt-Rasmussen U, Bolanowski M, Zhang SL, Yu Y, Witek P, Kalra P, Kietsiriroje N, Piacentini A, Pedroncelli AM, Samson SL. Feldt-Rasmussen U, et al. Front Endocrinol (Lausanne). 2024 Mar 21;15:1250822. doi: 10.3389/fendo.2024.1250822. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 38577574 Free PMC article. Clinical Trial.
INTRODUCTION: Pasireotide, a somatostatin receptor ligand, is approved for treating acromegaly and Cushing's disease (CD). ...METHODS: Participants with acromegaly or CD initiated long-acting pasireotide 40 mg/28 days intramuscularly (acromegaly) or pasireotide …
INTRODUCTION: Pasireotide, a somatostatin receptor ligand, is approved for treating acromegaly and Cushing's disease (CD). ...METHODS …
Predictors of biochemical response to somatostatin receptor ligands in acromegaly.
Marazuela M, Martínez-Hernandez R, Marques-Pamies M, Biagetti B, Araujo-Castro M, Puig-Domingo M. Marazuela M, et al. Best Pract Res Clin Endocrinol Metab. 2024 Mar 19:101893. doi: 10.1016/j.beem.2024.101893. Online ahead of print. Best Pract Res Clin Endocrinol Metab. 2024. PMID: 38575404 Review.
Although predictors of response to first-generation somatostatin receptor ligands (fg-SRLs), and to a lesser extent to pasireotide, have been studied in acromegaly for many years, their use is still not recommended in clinical guidelines. ...The aim of this review is to de …
Although predictors of response to first-generation somatostatin receptor ligands (fg-SRLs), and to a lesser extent to pasireotide, h …
Somatostatin: a possible mediator of the long-term effects of experimental vertical gastrectomy on glucose metabolism in rats?
Pérez-Arana GM, González-Domínguez Á, Visiedo F, Gómez AD, Bancalero-de Los Reyes J, Camacho-Ramírez A, Ribelles-García A, Almorza-Gomar D, Gracia-Romero M, Casar-García J, Prada-Oliveira JA. Pérez-Arana GM, et al. J Gastrointest Surg. 2024 Apr 2:S1091-255X(24)00398-6. doi: 10.1016/j.gassur.2024.03.035. Online ahead of print. J Gastrointest Surg. 2024. PMID: 38574966
Islet SST receptor (SSTR) and cell populations were studied. We performed a pasireotide (SST-28 analogue) infusion assay in another group of rats to confirm the influence of SST-28 plasma levels on the delta-cell population. ...The expression of SSTR type 5 in delta-cell p …
Islet SST receptor (SSTR) and cell populations were studied. We performed a pasireotide (SST-28 analogue) infusion assay in another g …
Long-term pasireotide therapy in acromegaly: extensive real-life experience of a referral center.
Pirchio R, Auriemma RS, Vergura A, Pivonello R, Colao A. Pirchio R, et al. J Endocrinol Invest. 2024 Mar 26. doi: 10.1007/s40618-023-02299-7. Online ahead of print. J Endocrinol Invest. 2024. PMID: 38532073
PURPOSE: Pasireotide is a novel therapeutic option for patients with acromegaly resistant to first-generation somatostatin receptor ligands. ...Patients who started with pasireotide 60 mg monthly exhibited significantly lower IGF-I levels after 36 months (p = 0.05) …
PURPOSE: Pasireotide is a novel therapeutic option for patients with acromegaly resistant to first-generation somatostatin receptor l …
IGF-2-mediated hypoglycemia: a case series and review of the medical therapies for refractory hypoglycemia.
Vu A, Chik C, Kwong S. Vu A, et al. Endocrinol Diabetes Metab Case Rep. 2024 Mar 1;2024(1):23-0089. doi: 10.1530/EDM-23-0089. Print 2024 Jan 1. Endocrinol Diabetes Metab Case Rep. 2024. PMID: 38432069 Free PMC article.
Available medical therapies to manage hypoglycemia include glucocorticoids, recombinant growth hormone, and pasireotide. We report two cases of IGF-2 mediated hypoglycemia. The first was managed surgically to good effect, highlighting the importance of a timely diagnosis t …
Available medical therapies to manage hypoglycemia include glucocorticoids, recombinant growth hormone, and pasireotide. We report tw …
Pharmacokinetics and pharmacodynamics of a pasireotide subcutaneous depot (CAM4071) and comparison with immediate and long-acting release pasireotide.
Johnsson M, Pedroncelli AM, Hansson A, Tiberg F. Johnsson M, et al. Endocrine. 2024 Feb 29. doi: 10.1007/s12020-024-03741-3. Online ahead of print. Endocrine. 2024. PMID: 38421556
After a single 600 g dose of pasireotide immediate release (IR), participants were randomised to one of eight groups to receive either a CAM4071 upper thigh (5, 10, 20, 40 or 80 mg) or buttock (20 mg) injection or multiple pasireotide IR 900 g upper thigh injections …
After a single 600 g dose of pasireotide immediate release (IR), participants were randomised to one of eight groups to receive eithe …
Management of pasireotide-induced hyperglycemia in patients with acromegaly: An experts' consensus statement.
Störmann S, Meyhöfer SM, Groener JB, Faust J, Schilbach K, Seufert J, Vergès B. Störmann S, et al. Front Endocrinol (Lausanne). 2024 Feb 9;15:1348990. doi: 10.3389/fendo.2024.1348990. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 38405148 Free PMC article.
Pasireotide is a somatostatin analogue for the treatment of acromegaly, a chronic condition caused by excess growth hormone. ...Here, we provide guidance on how to select appropriate patients with acromegaly for treatment with pasireotide. We summarize baseline char …
Pasireotide is a somatostatin analogue for the treatment of acromegaly, a chronic condition caused by excess growth hormone. ...Here, …
735 results